Heart failure: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 29
• GLP-1 6
• TTR 10
• AMPK 0
• NLRP3 0
• NRF2 0
• PI3K 0
• PPAR 0
• AKT 0
• mTOR 0
• HER2 2
• STAT3 0
• TP53 0
• MAPK 0
• SIRT1 0
• STING 0
• EGFR 0
• GIP 4
• HIF-1 0
• PCSK9 0
• DPP-4 0
• VEGF 0
• HMGB1 0
• IL-6 0
• CTNNB1 0
• TNF 0
• YAP 0
• PINK1 0
• ERK 0
• GPX4 0
• JAK 0
• TLR4 0
• IL-1 0
• JNK 0
• MEK 1
• HSP90 0
• DMD 0
• IL-17 0
• MMP-9 0
• PD-1 0
• CD40 0
• COX-2 0
• HDAC 0
• PD-L1 0
• TFEB 0
• ABL1 0
• APOE 0
• AR 0
• BCL-2 0
• FTO 0
• METTL3 0
• MYC 0
• PTEN 0
• ACE2 0
• BDNF 0
• BRAF 0
• BRD4 0
• BTK 0
• CDK4/6 0
• FAK 0

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until Aug 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spain· EU contribution €1,499,625· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  From n=1 to many: Scaling-up gene editing for future heart therapies (ONE2MANY)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,499,468· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  RAPid TranslatiOnal Research - Heart Failure (RAPTOR-HF)

  Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu· Wroclaw, Poland· EU contribution €15,000,000· until Dec 2032· 3 countries

5 of 84 running projects, newest first. Listed amounts together: €318.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

  NCT06338839· AstraZeneca· Updated 18 Sept 2025

  “The study was suspended after interim analysis to confirm reasonability of further investigation of the population”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Novo Nordisk A/S· Source

• A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Novo Nordisk A/S· Source

• Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· AstraZeneca· Source

• Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

  NCT06712030· Puerta de Hierro University Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 5
• Mendelian Randomization Analysis 79
• CRISPR-Cas Systems 7
• Gene Expression Profiling 71
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 10
• Proteomics 108
• Metabolomics 64
• Mass Spectrometry 5
• Flow Cytometry 10
• Immunohistochemistry 13
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 37
• Magnetic Resonance Imaging 155
• Machine Learning 198
• Deep Learning 42
• Cohort Studies 501
• Genome-Wide Association Study 74

• Association of Risk-Stratified WeChat-Based Tele-Nursing With Self-Care Outcomes and Short-Term Readmission Among Patients With Chronic Heart Failure: A Retrospective Cohort Study.

  Nurs Health Sci, Dec 2026

• Association between triglyceride-glucose body mass index and future risk of arthritis in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: A national prospective cohort study.

  Medicine (Baltimore), Nov 2026

• Importance of Angina Pectoris by Coronary Artery Disease Severity.

  JAMA Netw Open, Nov 2026

• Explainable Machine Learning for Predicting Incident Heart Failure from Routine Electronic Health Record Data.

  J Card Fail, Nov 2026

• Sex-related differences in outcome of tricuspid valve surgery in severe isolated secondary tricuspid regurgitation.

  Eur Heart J Cardiovasc Imaging, Oct 2026

• Prognostic value of cardiac magnetic resonance global T2 mapping in patients with takotsubo syndrome.

  Eur Heart J Cardiovasc Imaging, Oct 2026

• Incident transient ischemic attack and subsequent cardiovascular events and mortality in patients with newly diagnosed type 2 diabetes: a population-based cohort study.

  Front Endocrinol (Lausanne), Oct 2026

• Early Rhythm Control vs Usual Care After Acute Ischemic Stroke in Patients With Atrial Fibrillation.

  Neurology, Oct 2026

• Dataset-Agnostic Biological Age Calculator and Predictions of Mortality in NHANES (1999-2010), UK Biobank (2006-2010), and Dalian Heart Failure (2015-2023) Cohorts: Development and Validation Study.

  JMIR Form Res, Oct 2026

• Contemporary outcomes after 100 consecutive HeartMate 3 LVAD implantations: a single-centre cohort study from a Swiss tertiary centre.

  Swiss Med Wkly, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.